In this article, we will discuss Olaparib (Dosage Overview). So, let’s get started.
Maintenance Treatment of Recurrent Ovarian Cancer
Olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
Advanced gBRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy
Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline
BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Germline BRCA-mutated HER2-negative Metastatic Breast Cancer
Olaparib is indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
Important Administration Instructions
Olaparib is also available as a 50 mg capsule. Do not substitute Olaparib tablets (100 mg and 150 mg) with Olaparib capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.
The recommended dose of Olaparib is 300 mg (two 150 mg tablets) taken orally twice daily, with or without food, for a total daily dose of 600 mg. The 100 mg tablet is available for dose reduction.